Dossier assessment
Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients with moderate to severe psoriasis vulgaris who require systemic drug therapy
Result of dossier assessment:
No added benefit proven because of a lack of suitable study data
Project details
- Project no.
- A17-49
- Commission
- Commission awarded on 28.09.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dimethyl fumarate - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed